Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
What is your approach to a patient with rheumatoid arthritis and moderate disease activity on 25 mg of PO methotrexate?
Do you switch to SQ MTX, or is it best to add tx, such as a TNFi?
Answer from: at Community Practice
Switching to sub cu may work for low disease activity, but not moderate.
Sign in or Register to read more
10978
Related Questions
Do you use the peri-operative management of biologics and DMARDs guidelines, which were mainly based on total hip and knee replacement surgeries, for all peri-operative surgical management?
How do you approach managing nausea and GI side effects when initiating methotrexate?
How do you approach treatment of a patient with active RA and a history of Lynch Syndrome?
When considering a biologic for seropositive RA after failure of methotrexate or triple therapy, do you consider using abatacept as a first line biologic or would prefer choosing TNFi?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
When considering biologic therapy after failure of MTX or triple therapy, do you consider using Abatacept as a first line biologic?
How you do approach treatment for a patient with active seropositive RA (+RF/+CCP) who is receiving treatment for Hepatitis C?
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
What is your approach for cancer screening for elderly onset RA?